5 articles suggested by Yüksel Ürün
Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.
He suggested following few must-read papers on X:
1.”Next-generation clinical trials are breaking boundaries!
From tissue-agnostic designs to AI-powered precision medicine, the future is patient-centered, data-driven, and transformative.”
Novel clinical trial designs emerging from the molecular reclassification of cancer.
Authors: Mina Nikanjam, et al.
2.”Patients with suspected stage III-IV EOC should be evaluated by a gynecologic oncologist, with cancer antigen 125, computed tomography of the abdomen and pelvis, and chest imaging included.
All patients with EOC should be offered germline genetic and somatic testing at diagnosis.”
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update.
Authors: Stéphanie Gaillard, et al.
3.”Perioperative FLOT chemotherapy improved overall survival in resectable esophageal adenocarcinoma compared to preop chemoradiotherapy.
Progression-free survival also favored FLOT.”
Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer.
Authors: Jens Hoeppner, et al.
4.”1 in 3 men experience PSA persistence or relapse within 10 years post-radical prostatectomy.
Early relapse (<2 years) = higher PCa death risk (8.5%) vs. late relapse (>5 years, 1.4%).
Life expectancy and relapse timing guide treatment.”
Incidence and prognostic implications of PSA persistence and relapse after radical prostatectomy. Population-based study.
Authors: Pietro Scilipoti, et al.
5.”Exciting News!
Proud to share our latest research on the impact of comorbidities on survival in cancer patients receiving immune checkpoint inhibitors!
Great teamwork pays off!”
Impact of comorbidity on survival in cancer patients receiving immune checkpoint inhibitors.
Authors: Merih Yalçıner, et al.
More posts featuring Yüksel Ürün.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023